MUFG Securities EMEA plc Purchases 7,524 Shares of Stryker Corporation $SYK

MUFG Securities EMEA plc raised its position in shares of Stryker Corporation (NYSE:SYK) by 114.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 14,110 shares of the medical technology company’s stock after acquiring an additional 7,524 shares during the period. MUFG Securities EMEA plc’s holdings in Stryker were worth $4,959,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Godfrey Financial Associates Inc. bought a new position in shares of Stryker in the fourth quarter worth about $26,000. United Financial Planning Group LLC purchased a new stake in Stryker in the third quarter worth about $27,000. Strive Asset Management LLC purchased a new stake in Stryker in the third quarter worth about $30,000. CGC Financial Services LLC purchased a new stake in Stryker in the fourth quarter worth about $29,000. Finally, ANTIPODES PARTNERS Ltd purchased a new stake in Stryker in the third quarter worth about $34,000. 77.09% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 310,000 shares of the stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the transaction, the director owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. This represents a 13.87% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the transaction, the vice president owned 10,582 shares in the company, valued at approximately $3,247,298.34. This trade represents a 30.04% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 323,264 shares of company stock worth $100,659,489. 4.60% of the stock is owned by company insiders.

Stryker Stock Performance

SYK stock opened at $305.73 on Monday. The firm has a market cap of $117.21 billion, a price-to-earnings ratio of 35.39, a PEG ratio of 1.92 and a beta of 0.78. The firm has a 50-day simple moving average of $321.82 and a two-hundred day simple moving average of $348.10. Stryker Corporation has a one year low of $281.00 and a one year high of $404.87. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). The firm had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same period in the previous year, the company posted $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, equities analysts forecast that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 1.2%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is presently 40.74%.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Citigroup lowered their price objective on shares of Stryker from $420.00 to $385.00 and set a “buy” rating for the company in a research note on Tuesday, April 7th. UBS Group lowered their price objective on shares of Stryker from $400.00 to $380.00 and set a “neutral” rating for the company in a research note on Tuesday, March 17th. JPMorgan Chase & Co. lowered their price objective on shares of Stryker from $445.00 to $400.00 and set an “overweight” rating for the company in a research note on Friday, May 1st. William Blair reaffirmed an “outperform” rating on shares of Stryker in a research note on Thursday, March 5th. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $361.00 price objective on shares of Stryker in a research note on Friday, May 1st. Sixteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $395.48.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.